First author (country, year) | Type of study | No. of patients | Type of chemotherapy | T3-4 | N+ | Any Gr ≥ 3 tox. | Gr > 3 Hem. tox. | Gr > 3 Non- hem. tox. | Toxic deaths | Relapse rate | Median survival (months) |
---|---|---|---|---|---|---|---|---|---|---|---|
MacDonald [4] (USA, 2001) | Phase 3 | 556 | 5FU/LV1 | 66% | 85% | 41% | 54% | 63% | 1% | 43% | 36 |
Park [18] (South-Korea,2003) | Phase 2 | 290 | 5FU/LV | NA | 90% | NA | 30% | 38% | 0% | 39% | NA |
Hughes [14] (Australia, 2004) | Retrosp. | 452 | 5FU/LV | 85% | 81% | 42% | 18% | 20% | 0% | 68% | 22.8 |
Kollmannsberger [20] (Germany, 2005) | Phase 2 | 86 | DDP/5FU PAC/DDP/5FU/LV4 | NA | NA | NA | 81% 89% | 56% 56% | 0% 0% | 19% 33% | NA NA |
Kim [9] (South Korea, 2005) | Retrosp. | 990 | 5FU/LV | 48% | 93% | NA | 30% | 15% | 1% | 42% | 95 |
Kassam [15] (Canada, 2006) | Retrosp. | 822 | 5FU/LV3 DDP/5FU | 53% | 82% | 56% | 33% | 34% | 0% | 32% | NR |
Lee [19] (South-Korea, 2006) | Phase 2 | 31 | DDP/5FU | NA | 100% | NA | 66% | 12% | 0% | 13% | NA |
Oechsle [8] (Germany,2007) | Phase 2 | 157 | DDP/PAC/5FU/LV | NA | NA | NA | 100% | 58% | 0.6%5 | 51% | NA |
DDP/5FU/LV | 93% | 59% | 52% | NA | |||||||
CPT11/5FU/LV | 80% | 73% | 100% | NA | |||||||
DOC/DDP/5FU | 100% | 30% | 30% | NA | |||||||
Tsang13] (Hong Kong, 2008) | Retrosp. | 632 | 5FU/LV | 52% | 86% | 30% | 24% | 14% | 1.5% | 52% | NR |
Hofheinz [16] Germany, 2008) | Extend. phase I | 322 | CAPE/OXALI | 44% | 97% | NA | 21% | 42% | 0% | 47% | NA |
Di Costanzo [7] (Italy, 2008) | Phase 3 | 258 | DDP/EPI/5FU/LV1 | 54% | 84% | NR | 27% | 75% | 0.8% | 48% | 57 |
Leong [22] (Australia, 2009) | Phase 2 | 54 | EPI/DDP/5FU | 57% | 98% | NA | 28% | 66% | 0% | 37% | NR |
Aftimos [21] (Lebanon, 2010) | Retrosp. | 24 | 5FU/LV DDP/5FU | 75% | 71% | NA | 20% | 36% | 0% | 22% | 75 |
Chang [17] (Hong Kong, 2011) | Retrosp. | 1202 | 5FU/LV | 45% | 93% | 66% | 61% | 15% | 0% | 41% | 64 |
Current (Israel, 2011) | Retrosp. | 166 | 5FU/LV | 77% | 85% | 46% | 32% | 25% | 1.8% | 30% | NR |